Cost Is an Adherence Problem — and a Clinical One

When a patient with glaucoma doesn't fill their Bimatoprost prescription, the consequence isn't a mild inconvenience — it's progressive, irreversible vision loss. And yet, cost remains one of the biggest reasons patients skip doses or abandon treatment entirely.

The numbers tell the story: brand-name Lumigan can exceed $200 to $300 per bottle, and even generic Bimatoprost runs $50 to $120 at cash price without coupons. For patients on fixed incomes or with high-deductible plans, that's a meaningful barrier. Latisse, prescribed for hypotrichosis, is almost never covered by insurance since it's classified as cosmetic.

As a provider, you can't control drug prices — but you can equip your patients (and your staff) with the tools to minimize out-of-pocket costs. This guide covers every major savings pathway available for Bimatoprost in 2026.

What Your Patients Are Actually Paying

Before recommending savings strategies, it helps to understand the pricing landscape:

• Generic Bimatoprost 0.01% or 0.03% — $50 to $120 per 2.5-5 mL bottle (cash price without insurance or coupons)
• Generic Bimatoprost with discount card — As low as $0.87 (GoodRx, SingleCare, or similar)
• Lumigan (brand) — $200 to $300+ per bottle
• Latisse (brand, for eyelash growth) — $120 to $180 per 3 mL bottle
• Durysta implant — Procedure pricing varies; typically billed under medical benefit, not pharmacy

The delta between "sticker price" and "actual available price" is enormous for Bimatoprost. Many patients simply don't know that discount cards exist or that generic Bimatoprost is available. A 30-second conversation in your office can save them hundreds of dollars per year.

Manufacturer Savings Programs

AbbVie At Your Service (Lumigan)

AbbVie offers a co-pay savings program for commercially insured patients using brand-name Lumigan. Key details:

• Up to $2,640 per calendar year in co-pay assistance
• Available to commercially insured patients (not valid for Medicare, Medicaid, or other government-funded programs)
• Patients can enroll through abbvie.com or by calling the program directly
• Your office staff can help patients access enrollment during their visit

Durysta Savings Program

For patients receiving the Durysta intracameral implant, AbbVie/IQVIA offers a separate savings program. Since Durysta is typically billed under medical benefits, this program helps offset the patient's cost-sharing for the procedure.

Allergan Patient Assistance Program (PAP)

For uninsured or underinsured patients who meet income requirements, AbbVie's Patient Assistance Program provides Allergan medications (including Lumigan) at no cost. Key details:

• Income-based eligibility
• Application available through abbvie.com or via provider submission
• Processing typically takes 4 to 6 weeks, so plan ahead
• Covers brand products only, not generic

If your practice regularly prescribes Lumigan or Durysta, consider keeping PAP applications on hand or bookmarking the enrollment portal for your support staff.

Coupon and Discount Cards

For patients paying cash or facing high co-pays on generic Bimatoprost, third-party discount cards can dramatically reduce the price:

• GoodRx — Shows pharmacy-specific pricing; generic Bimatoprost has been listed as low as $0.87
• SingleCare — Another widely accepted discount card with competitive pricing
• RxSaver, Optum Perks, BuzzRx — Additional options that may offer lower prices at certain pharmacies
• Costco membership pharmacy — Often has lower cash prices on generics, even for non-members (pharmacy is accessible without membership in most states)

These cards are free, require no income verification, and can be used by insured patients when the discount price is lower than their insurance co-pay. Your staff can print a GoodRx coupon in the office or direct patients to download the app.

For a comprehensive patient-facing guide, refer patients to our article on saving money on Bimatoprost.

Generic Alternatives and Therapeutic Substitution

Generic Bimatoprost

Generic Bimatoprost ophthalmic solution is available in both the 0.01% and 0.03% concentrations. It's manufactured by several companies, including Amneal Pharmaceuticals (which received FDA approval for the 0.01% formulation in 2025). Generic versions are bioequivalent to brand Lumigan and are vastly cheaper.

If a patient is currently on brand Lumigan and cost is a concern, switching to generic Bimatoprost should be the first conversation. In most cases, the pharmacy can make this substitution automatically unless the prescription specifies "brand medically necessary."

Therapeutic Alternatives

If Bimatoprost itself is too expensive or unavailable, consider therapeutic substitution within the prostaglandin analog class:

• Latanoprost (generic Xalatan) — The most affordable prostaglandin analog, widely available as a generic for under $15 with discount cards. Similar IOP-lowering efficacy, though some studies suggest Bimatoprost may provide slightly greater reduction (1-2 mmHg).
• Travoprost (generic Travatan Z) — Another option with similar efficacy. May be preferred for patients sensitive to benzalkonium chloride preservative (Travatan Z uses sofZia preservative).
• Tafluprost (Zioptan) — Preservative-free single-dose vials. Good for patients with preservative sensitivity, though potentially slightly less effective and more expensive.

For a detailed comparison, see our guide on alternatives to Bimatoprost.

Building Cost Conversations Into Your Workflow

Many providers find it challenging to discuss medication costs during already-packed appointments. Here are practical strategies:

At the Point of Prescribing

• Default to generic — Write prescriptions for "Bimatoprost" rather than "Lumigan" unless there's a clinical reason for brand
• Mention cost proactively — "This is available as a generic, which is much more affordable. There are also discount cards that can bring the price down significantly."
• Consider formulary — Check the patient's insurance formulary before prescribing. If Latanoprost is preferred and clinically appropriate, it may be the most cost-effective first choice

Empower Your Staff

• Train front-desk and technician staff to hand out GoodRx/SingleCare information with every new glaucoma prescription
• Keep manufacturer co-pay card enrollment forms accessible
• Post a simple reference card at the checkout area listing available savings resources
• Designate a staff member as the "cost navigator" for patients who report difficulty filling prescriptions

At Follow-Up Visits

• Ask directly: "Have you been able to fill your Bimatoprost prescription without any issues?"
• If a patient reports cost barriers, explore the options above before considering therapeutic changes
• Document cost-related adherence concerns in the chart — it's clinically relevant

Use Medfinder for Availability

If patients report that their pharmacy doesn't have Bimatoprost in stock, direct them to Medfinder for Providers to help locate pharmacies with current availability. This is especially useful during periods of intermittent supply disruptions.

Final Thoughts

Bimatoprost adherence is directly tied to outcomes — a patient who can't afford their drops will stop using them, and glaucoma progression doesn't wait. The good news is that with generic availability and discount programs, most patients can access Bimatoprost for a fraction of the sticker price.

Your role as a provider isn't to navigate insurance systems for every patient — but a little guidance goes a long way. Defaulting to generic, mentioning discount cards, and keeping manufacturer savings resources accessible can meaningfully improve adherence across your glaucoma patient population.

For additional provider resources, including availability tracking and patient tools, visit Medfinder for Providers.